Correlation Between Amicus Therapeutics and Agios Pharm

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Amicus Therapeutics and Agios Pharm at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amicus Therapeutics and Agios Pharm into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Amicus Therapeutics and Agios Pharm, you can compare the effects of market volatilities on Amicus Therapeutics and Agios Pharm and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amicus Therapeutics with a short position of Agios Pharm. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amicus Therapeutics and Agios Pharm.

Diversification Opportunities for Amicus Therapeutics and Agios Pharm

-0.5
  Correlation Coefficient

Very good diversification

The 3 months correlation between Amicus and Agios is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and Agios Pharm in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Agios Pharm and Amicus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amicus Therapeutics are associated (or correlated) with Agios Pharm. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Agios Pharm has no effect on the direction of Amicus Therapeutics i.e., Amicus Therapeutics and Agios Pharm go up and down completely randomly.

Pair Corralation between Amicus Therapeutics and Agios Pharm

Given the investment horizon of 90 days Amicus Therapeutics is expected to under-perform the Agios Pharm. But the stock apears to be less risky and, when comparing its historical volatility, Amicus Therapeutics is 1.17 times less risky than Agios Pharm. The stock trades about -0.1 of its potential returns per unit of risk. The Agios Pharm is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  4,404  in Agios Pharm on September 5, 2024 and sell it today you would earn a total of  1,484  from holding Agios Pharm or generate 33.7% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Amicus Therapeutics  vs.  Agios Pharm

 Performance 
       Timeline  
Amicus Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Amicus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Agios Pharm 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Agios Pharm are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating forward indicators, Agios Pharm displayed solid returns over the last few months and may actually be approaching a breakup point.

Amicus Therapeutics and Agios Pharm Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Amicus Therapeutics and Agios Pharm

The main advantage of trading using opposite Amicus Therapeutics and Agios Pharm positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amicus Therapeutics position performs unexpectedly, Agios Pharm can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will offset losses from the drop in Agios Pharm's long position.
The idea behind Amicus Therapeutics and Agios Pharm pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance